• Chemicals
• Discovery / R&D
• Generics
• Market Trends
• Pharma Industry Trends
• Pricing & Reimbursement
• Regulatory
• Sales & Marketing
• Therapeutic

M&A in pharma

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy

The global cardiovascular market grew to US$89.7 billion in 2005, a year-on-year increase of 9.6%

The global cardiovascular market is forecast to expand to US$116.3 billion in 2010, equivalent to a CAGR of 5.3% over the next five years. The slow-down in cardiovascular market growth between 2003 and 2005 is forecast to continue through to 2010. While continued changes in demographics and lifestyle will continue to drive cardiovascular sales forward, growth rates will be limited by continued patent expiries for major products and a dearth of novel therapies being introduced.

Cardiovascular Pharmaceutical Market Trends, 2007 to 2010 - Key market forecasts and growth opportunities provides an in-depth analysis of the growing market for pharmaceutical treatments for cardiovascular disorders including:

• Coronary heart disease
• Cerebrovascular disease
• Peripheral arterial disease
• Rheumatic heart disease
• Congenital heart disease
• Deep vein thrombosis and pulmonary embolism

This comprehensive report, from URCH Publishing, delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.

Key findings from the report include:

• The global market for cardiovascular patients will increase to 251 million in 2010, with the greatest rate of growth forecast for the US market.
• The anti-hypertensives drug class dominates the global cardiovascular market with a market share of nearly 50%.
• Of the top 20 products by global cardiovascular sales in 2005, all 20 generated annual sales in excess of US$1 billion.
• The top 20 products in 2005 contributed sales of US$59.3 billion accounting for 66.1% of the total cardiovascular market.
• A total of 14 pharmaceutical companies were identified as having generated cardiovascular sales in excess of US$1 billion in 2005.
• The leading cardiovascular drug projected to achieve the greatest growth over the next five years is Takeda/ AstraZeneca's Blopress/ Atacand (candesartan) with a CAGR of 9.0%

This report provides key information needed in your business including:

• Sales forecast for top ten companies providing cardiovascular treatment medicines.
• Analysis of leading cardiovascular products likely to loose patent protection in the next ten years.
• Sales forecasts to 2010 for the top ten cardio medicines and forecasts by drug class.
• Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
• Breakdown of the major market trends and business opportunities
• In-depth coverage of the following companies' cardio market presence: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi-Aventis, Servier.

Use This Report To:
1. Benchmark your company's portfolio against market trends and forecasts to plan better for greater profitability.

2. Indentify areas of potential pharmaceutical market growth and good opportunities for delivering successful sales growth

3. Support your internal business planning processes by using an external perspective founded on detailed analysis and solid market forecasts.

The 112 page publication contains 40 Figures and 46 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:
- pharmaceutical company corporate planning,
- sales and marketing strategy,
- portfolio management, and,
- market and sales forecasting.

The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future cardiovascular market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding cardiovascular market trends.

Summary
Introduction
Key disease markets
Key drug classes
Key products
Key companies
Key trends and opportunities

Chapter 1. Introduction
Global cardiovascular market
Report overview

Chapter 2. Key disease markets
Key cardiovascular markets
Cardiovascular epidemiology

Chapter 3. Key drug classes
Key drug classifications
Anti-hypertensive drug class
Anti-dyslipidemics drug class
Anti-thrombotics drug class
Selected others drug class

Chapter 4. Key products
Leading products Top 10 leading cardiovascular drugs

Chapter 5. Key companies
Major cardiovascular players Leading companies

Chapter 6. Key trends and opportunities
Key disease market forecasts

Key drug class forecasts

Key product forecasts
Key company forecasts

Appendix
Proprietary data sources

Top 58 cardiovascular products
Top 14 pharmaceutical companies by cardiovascular sales

LIST OF FIGURES
Figure 1: Global cardiovascular market, 2003-2005
Figure 2: Report structure
Figure 3: Disease burden for cardio in seven major pharmaceutical markets, 2005
Figure 4: Prevalence for cardio in seven major pharmaceutical markets, 2005
Figure 5: Cardio deaths in seven major pharmaceutical markets, 2005
Figure 6: Hypertension epidemiology in seven major markets, 2005
Figure 7: Dyslipidemia epidemiology in seven major markets, 2005
Figure 8: Coronary heart disease epidemiology in seven major markets, 2005
Figure 9: Global cardiovascular market by drug class, 2005
Figure 10: Global cardiovascular market by drug class, 2003-2005
Figure 11: Global cardiovascular market trends by drug class, 2004-2005
Figure 12: Anti-hypertensives market, 2003-2005
Figure 13: Leading anti-hypertensive drugs by approval date, 1974-2005
Figure 14: Anti-dyslipidemics market, 2003-2005
Figure 15: Leading anti-dyslipidemic drugs by approval date, 1991-2005
Figure 16: Anti-thrombotic market, 2003-2005
Figure 17: Leading anti-thrombotic drugs by approval date, 1954-2005
Figure 18: Cardiovascular selected others market, 2003-2005
Figure 19: Leading cardiovascular selected others drugs by approval date, 1971-2005
Figure 20: Top 10 cardiovascular products by global sales, 2005
Figure 21: Top 10 companies by global cardiovascular sales, 2005
Figure 22: Top 10 companies by global cardiovascular market share, 2005
Figure 23: Top 10 companies by global cardiovascular sales, 2004-2005
Figure 24: Cardiovascular prevalence forecasts by geographic market, 2005-2010
Figure 25: Cardiovascular prevalence forecasts by disease market, 2005-2010
Figure 26: Global cardiovascular market forecast, 2003-2010
Figure 27: Global cardiovascular market forecasts by drug class, 2003-2010
Figure 28: Top 10 cardiovascular drugs by forecast sales, 2010
Figure 29: Lipitor (atorvastatin) forecast sales, 2003-2010
Figure 30: Plavix (clopidogel) forecast sales, 2003-2010
Figure 31: Norvasc/ Amlodin (amlodopine) forecast sales, 2003-2010
Figure 32: Zocor (simvastatin) forecast sales, 2003-2010
Figure 33: Diovan/Co-Diovan (valsartan) forecast sales, 2003-2010
Figure 34: Pravachol/ Mevalotin (pravastatin) forecast sales, 2003-2010
Figure 35: Cozaar/ Hyzaar (losartan) forecast sales, 2003-2010
Figure 36: Lovenox (enoxaparin) forecast sales, 2003-2010
Figure 37: Blopress/ Atacand (candesartan) forecast sales, 2003-2010
Figure 38: Aprovel/ Avapro/ Avalide (irbesartan) forecast sales, 2003-2010
Figure 39: Forecast patent expiries by 2005 global sales, 2006-2015
Figure 40: Top ten companies by cardiovascular sales trends, 2005-2010

LIST OF TABLES
Table 1: Global cardiovascular market trends by drug class, 2003-2005
Table 2: Leading anti-hypertensives drugs, 2005
Table 3: Anti-hypertensives market trends, 2003-2005
Table 4: Leading anti-dyslipidemic drugs, 2005
Table 5: Anti-dyslipidemics market trends, 2003-2005
Table 6: Leading anti-thrombotic drugs, 2005
Table 7: Anti-thrombotic market trends, 2003-2005
Table 8: Leading cardiovascular selected others drugs, 2005
Table 9: Cardiovascular selected others market trends, 2003-2005
Table 10: Top 20 cardiovascular products by global sales, 2003-2005
Table 11: Lipitor (atorvastatin) profile, 2005
Table 12: Plavix (clopidogel) profile, 2005
Table 13: Norvasc/ Amlodin (amlodopine) profile, 2005
Table 14: Zocor (simvastatin) profile, 2005
Table 15: Diovan/ Co-Diovan (valsartan) profile, 2005
Table 16: Pravachol/ Mevalotin (pravastatin) profile, 2005
Table 17: Cozaar/ Hyzaar (losartan) profile, 2005
Table 18: Lovenox (enoxaparin) profile, 2005
Table 19: Blopress/ Atacand (candesartan) profile, 2005
Table 20: Aprovel/ Avapro/ Avalide (irbesartan) profile, 2005
Table 21: Top 10 companies by global cardiovascular sales, 2003-2005
Table 22: Pfizer profile, 2005
Table 23: Pfizer cardiovascular pipeline, 2005
Table 24: Merck profile, 2005
Table 25: Merck cardiovascular pipeline, 2005
Table 26: Sanofi-Aventis profile, 2005
Table 27: Sanofi-Aventis cardiovascular pipeline, 2005
Table 28: Bristol-Myers Squibb profile, 2005
Table 29: Bristol-Myers Squibb cardiovascular pipeline, 2005
Table 30: Novartis profile, 2005
Table 31: Novartis cardiovascular pipeline, 2005
Table 32: AstraZeneca profile, 2005
Table 33: AstraZeneca cardiovascular pipeline, 2005
Table 34: Daiichi Sankyo profile, 2005
Table 35: Daiichi Sankyo cardiovascular pipeline, 2005
Table 36: Servier profile, 2005
Table 37: Servier cardiovascular pipeline, 2005
Table 38: GlaxoSmithKline profile, 2005
Table 39: GlaxoSmithKline cardiovascular pipeline, 2005
Table 40: Boehringer Ingelheim profile, 2005
Table 41: Boehringer Ingelheim cardiovascular pipeline, 2005
Table 42: Global cardiovascular market forecasts by drug class, 2003-2010
Table 43: Top 10 cardiovascular drugs forecasts, 2003-2010
Table 44: Top 10 companies by cardiovascular sales forecasts, 2005-2010
Table 45: Top 58 cardiovascular products by global pharmaceutical sales, 2003-2005
Table 46: Top 14 companies by global cardiovascular sales, 2003-2005

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA from the London Business School.